The National Medical Products Administration (NMPA) has cleared Yochanra (tinengotinib) for adult patients with unresectable ...

The diagnostics and life sciences tools sector is attracting continued investor interest across both private equity and large ...

Koray Kavukcuoglu, DeepMind's chief technology officer and Google's chief AI architect, is taking on the operational ...

At its third attempt, Replimune has finally won FDA approval for its advanced melanoma treatment RP1, giving the company its ...

Tarsus is paying $450 million upfront for Alkeus – made up of $270 million in cash and $180 million in stock – with another ...

Takeda's orexin agonist Orzeyful has been approved in the US to treat narcolepsy type 1 (NT1) in adults, becoming the first ...

Scribe Therapeutics has become the latest biotech to list on the Nasdaq in the US, raising more than $155 million to advance ...

For an emerging biopharma company developing an innovative therapy for a rare condition, 2026 presents a dilemma that may ...

Under the terms of the deal, ‌Lantheus' shareholders will get $102.50 per share in cash when the deal closes, along with the ...

There's a change at the helm of Johnson & Johnson's pharma division in the offing, as executive vice president Jennifer ...

Moderna has started first-in-human testing of its mRNA vaccine against Bundibugyo Ebola virus (BDBV), now causing the ...

For decades, direct-to-consumer (DTC) advertising has been a defining feature of the US healthcare system. Across the nation, ...